Users Stopping Anti-Obesity Medications Gain Back Pounds Far More Rapidly Compared to People Using Diet and Exercise

Fresh analysis indicates that individuals who discontinue new GLP-1 drugs like Mounjaro or Wegovy may regain lost weight much more quickly than those who end conventional diet and exercise regimens.

Findings released in a major health publication demonstrates that while overweight individuals frequently drop a large proportion of their total mass while on the medication, the mass returns at an estimated rate of 0.8 kg per month after stopping.

"Users buying these treatments need to be cognizant of the danger of rapid rebound weight gain when the therapy is stopped," warns lead investigator Dr. Susan Jebb.

That rate of recovery suggests a return to starting mass within about one and a half years.

Analyzing Treatments

The analysis, which examined 37 of studies involving thousands of patients, compared the results of the injectable medications with conventional dieting.

Scientists point out that people who lose weight through lifestyle changes alone generally have a slower weight regain—approximately 100 grams monthly—post-intervention.

The Reason for the Fast Rebound

Experts suggest the mechanism of the injections explains the accelerated rebound.

These medications mimic a body's own chemical called glucagon-like peptide-1, which controls hunger.

"Artificially providing the hormone concentrations far above than normal may cause the body to generate a reduced amount of its own natural GLP-1, and could reduce sensitivity to its actions," said Dr. Adam Collins, a dietetics specialist.

"Stopping of this GLP-1 'fix' results in appetite is no longer kept in check, making binge eating far more likely."

A Lifelong Condition?

Health authorities advise the jabs for individuals with weight-linked medical conditions, alongside prescribed diet and exercise modifications.

A number of clinicians contend that, given the likelihood of weight regain, the therapy should be considered ongoing.

This opinion is supported by pharmaceutical companies, who say that the results "underscore the persistent nature of obesity," similar to managing diseases like high blood pressure.

Patient Accounts

People who have come off the jabs explain a intense resurgence of hunger.

"It felt as if something activating and you become starving," said a patient.

This challenge is exacerbated if patients have not developed lasting dietary or behavioural changes during therapy.

Growing Interest

Survey data suggest that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with interest remaining high.

• Adoption is greater among women than men.
• The 40s and 50s demographic shows the highest usage rates.
• Many access the medications through private prescriptions rather than the NHS.

Finally, researchers emphasize that while these medications are effective agents for weight loss, they are not a magic cure and lasting health benefits relies on ongoing behavioural changes.